Motilal Oswal initiates "buy" call on Mankind Pharma with a target price of Rs 2,650.
Motilal Oswal initiated coverage on Mankind Pharma with a 'buy' call and a target price of Rs 2,650, considering strong brand visibility, sustainable growth and superior return ratios. The firm assigned a 40x multiple on 12M forward earnings, representing a 30% premium to the pharma sector's valuation. Mankind Pharma has established its DF business through a disruptive strategy in tier II and below cities.
June 13, 2024
3 Articles